Inspire Medical Systems, Inc. $INSP Shares Purchased by Intech Investment Management LLC

Intech Investment Management LLC boosted its position in Inspire Medical Systems, Inc. (NYSE:INSP) by 166.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 34,094 shares of the company’s stock after purchasing an additional 21,297 shares during the quarter. Intech Investment Management LLC owned about 0.12% of Inspire Medical Systems worth $5,430,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Parallel Advisors LLC raised its stake in Inspire Medical Systems by 356.5% in the 1st quarter. Parallel Advisors LLC now owns 210 shares of the company’s stock valued at $33,000 after purchasing an additional 164 shares during the last quarter. Quarry LP raised its stake in Inspire Medical Systems by 2,127.3% in the 1st quarter. Quarry LP now owns 245 shares of the company’s stock valued at $39,000 after purchasing an additional 234 shares during the last quarter. Banque Transatlantique SA acquired a new position in Inspire Medical Systems in the 1st quarter valued at $46,000. Smartleaf Asset Management LLC raised its holdings in shares of Inspire Medical Systems by 27.2% during the 1st quarter. Smartleaf Asset Management LLC now owns 454 shares of the company’s stock worth $71,000 after acquiring an additional 97 shares during the period. Finally, GAMMA Investing LLC increased its position in Inspire Medical Systems by 253.7% during the first quarter. GAMMA Investing LLC now owns 573 shares of the company’s stock worth $91,000 after purchasing an additional 411 shares during the last quarter. 94.91% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Richard Buchholz sold 11,000 shares of the firm’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $93.39, for a total transaction of $1,027,290.00. Following the completion of the transaction, the chief financial officer directly owned 44,867 shares in the company, valued at $4,190,129.13. This trade represents a 19.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 4.10% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Truist Financial restated a “hold” rating and set a $125.00 price objective (down from $190.00) on shares of Inspire Medical Systems in a research report on Tuesday, August 5th. KeyCorp downgraded Inspire Medical Systems from an “overweight” rating to a “sector weight” rating in a research report on Tuesday, August 5th. Lake Street Capital set a $150.00 price objective on Inspire Medical Systems and gave the stock a “buy” rating in a research report on Tuesday, August 5th. UBS Group set a $230.00 price objective on Inspire Medical Systems and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Finally, Royal Bank Of Canada cut their price objective on Inspire Medical Systems from $215.00 to $180.00 and set an “outperform” rating for the company in a research report on Tuesday, August 5th. Eight analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $164.50.

Inspire Medical Systems Price Performance

Shares of Inspire Medical Systems stock opened at $82.62 on Friday. The business has a 50-day moving average of $105.81 and a 200 day moving average of $135.64. Inspire Medical Systems, Inc. has a 12 month low of $73.92 and a 12 month high of $218.52. The stock has a market capitalization of $2.44 billion, a price-to-earnings ratio of 47.76, a price-to-earnings-growth ratio of 2.46 and a beta of 1.15.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Monday, August 4th. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.23. Inspire Medical Systems had a return on equity of 10.38% and a net margin of 6.17%.The company had revenue of $217.09 million during the quarter, compared to analysts’ expectations of $214.50 million. During the same period last year, the business posted $0.32 EPS. Inspire Medical Systems’s revenue for the quarter was up 10.8% on a year-over-year basis. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS. Equities research analysts anticipate that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

Inspire Medical Systems declared that its Board of Directors has approved a share repurchase plan on Monday, August 11th that permits the company to buyback $200.00 million in shares. This buyback authorization permits the company to repurchase up to 8.6% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.